Medtronic (NYSE: MDT) Sees Strong Growth and Positive Outlook

Font: Financial Modeling Prep  • Jun 03, 2026

• Medtronic's strong financial performance, including a decade-high top-line growth and a maintained "Buy" rating from Needham, highlights its robust market position in medical technology.
• The Cardiac Ablation Solutions business is a significant growth driver, achieving impressive revenue growth of 78% globally and 124% in the U.S., leading to substantial market share gains.
• Despite cautious full-year EPS guidance due to external challenges, Medtronic is strategically investing in innovation and key growth sectors, projecting solid organic revenue growth for fiscal year 2027.

Medtronic (NYSE: MDT) is a global leader in medical technology, developing and manufacturing a wide range of medical devices and therapies. The company operates in areas like cardiovascular health, medical surgical, neuroscience, and diabetes. It competes with other major healthcare companies such as Johnson & Johnson and Boston Scientific.

Needham has maintained its Buy rating for Medtronic. This positive outlook is supported by the company's strongest top-line performance in a decade. Following the news, the stock price increased by 5.46%, with the rating released when the price was $77.74. The company reported a fourth-quarter revenue of $9.8 billion.

A key driver for this performance is the Cardiac Ablation Solutions business. As highlighted by Zacks, this segment's revenue grew by 78% globally and an impressive 124% in the United States. This growth helped Medtronic gain 8 points of market share in the U.S. and puts the segment on track for $2 billion in revenue.

Medtronic reported fourth-quarter adjusted earnings per share (EPS) of $1.55, which beat analyst estimates. For the full fiscal year 2026, adjusted EPS was $5.53. Looking ahead, the company projects organic revenue growth of 6.75% to 7.25% for fiscal year 2027, driven by key growth sectors.

However, the company's full-year EPS guidance of $5.90 to $6.00 is cautious. Management cites challenges such as tariff pressures and costs related to acquisitions. Strategically, Medtronic is investing in innovation, including ICE catheter technology, and has successfully completed the IPO for its MiniMed business.